Omnicare Earnings Preview
Omnicare (NYS: OCR) will try to beat its earnings estimates for the third consecutive quarter. The company will unveil its latest earnings on Thursday, Feb. 23. Omnicare is a geriatric pharmaceutical services company that provides pharmaceuticals and related ancillary pharmacy services to long-term health-care institutions.
What analysts say:
- Buy, sell, or hold?: The majority of analysts back Omnicare as a buy. But with 55.6% of analysts rating it a buy, Omnicare is still below the mean analyst rating of its nearest 10 competitors, which average 62.1% buys. Analysts like Omnicare better than competitor Tenet Healthcare overall. Seven out of 17 analysts rate Tenet Healthcare a buy compared to five of nine for Omnicare. Analysts haven't adjusted their rating of Omnicare for the past three months.
- Revenue forecasts: On average, analysts predict $1.52 billion in revenue this quarter. That would represent a decline of 2.6% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.56 per share. Estimates range from $0.54 to $0.57.
What our community says:
CAPS All-Stars are strongly supporting the stock, with 96.5% granting it an "outperform" rating. Most of the community is in line with the All-Stars, with 91.8% giving it a rating of "outperform." Despite the majority sentiment in favor of Omnicare, the stock has a middling CAPS rating of three out of five stars.
A year-over-year revenue decrease last quarter snaps a streak of three consecutive quarters of revenue increases.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Omnicare now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.
At the time this article was published
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.